Antifungal Treatment for Blastomycosis in Patients Using Proton Pump Inhibitors
Rationale for Antifungal Selection
- The Infectious Diseases Society of America recommends fluconazole as the preferred antifungal agent for treating blastomycosis in patients using proton pump inhibitors, as it does not require gastric acidity for absorption and demonstrates efficacy at higher doses of 400-800 mg daily 1, 2
- Itraconazole capsules require gastric acidity for optimal absorption, which is significantly reduced by proton pump inhibitors, according to the Clinical Infectious Diseases guidelines 1, 2
- Fluconazole absorption is not affected by gastric pH, making it suitable for patients on acid-suppressive therapy, as stated by the Clinical Infectious Diseases guidelines 1, 2
Efficacy Considerations
- Higher doses of fluconazole (400-800 mg daily) have demonstrated 87% success rates in treating blastomycosis, with a moderate strength of evidence 2
- Itraconazole generally has greater intrinsic activity against B. dermatitidis than fluconazole when properly absorbed, according to the Clinical Infectious Diseases guidelines 2, 3
Treatment Algorithm
- For non-life-threatening, non-CNS blastomycosis, the first choice is fluconazole 400-800 mg daily for 6-12 months, as recommended by the Clinical Infectious Diseases guidelines 1
- For life-threatening or CNS blastomycosis, initial therapy is lipid formulation of amphotericin B at 3-5 mg/kg/day for 1-2 weeks, followed by step-down therapy with fluconazole 800 mg daily for CNS involvement, as stated by the Clinical Infectious Diseases guidelines 4, 5
Monitoring Recommendations
- For patients on fluconazole, monitor hepatic enzymes before starting therapy, at 2 and 4 weeks, then every 3 months, as recommended by the Clinical Infectious Diseases guidelines 1, 2
- For patients on itraconazole solution, measure serum levels after 2 weeks of therapy to ensure adequate drug exposure (target >1.0 μg/mL), according to the Clinical Infectious Diseases guidelines 1, 5
Important Caveats and Considerations
- Echinocandins (caspofungin, micafungin, anidulafungin) have poor activity against B. dermatitidis and should not be used, as stated by the Clinical Infectious Diseases guidelines 1
- Treatment duration should be at least 6-12 months, with longer courses for immunocompromised patients, according to the Clinical Infectious Diseases guidelines 2